49 results on '"Herms, Jochen"'
Search Results
2. Tau deposition patterns are associated with functional connectivity in primary tauopathies
- Author
-
Franzmeier, Nicolai, Brendel, Matthias, Beyer, Leonie, Slemann, Luna, Kovacs, Gabor G, Arzberger, Thomas, Kurz, Carolin, Respondek, Gesine, Lukic, Milica J, Biel, Davina, Rubinski, Anna, Frontzkowski, Lukas, Hummel, Selina, Müller, Andre, Finze, Anika, Palleis, Carla, Joseph, Emanuel, Weidinger, Endy, Katzdobler, Sabrina, Song, Mengmeng, Biechele, Gloria, Kern, Maike, Scheifele, Maximilian, Rauchmann, Boris-Stephan, Perneczky, Robert, Rullman, Michael, Patt, Marianne, Schildan, Andreas, Barthel, Henryk, Sabri, Osama, Rumpf, Jost J, Schroeter, Matthias L, Classen, Joseph, Villemagne, Victor, Seibyl, John, Stephens, Andrew W, Lee, Edward B, Coughlin, David G, Giese, Armin, Grossman, Murray, McMillan, Corey T, Gelpi, Ellen, Molina-Porcel, Laura, Compta, Yaroslau, van Swieten, John C, Laat, Laura Donker, Troakes, Claire, Al-Sarraj, Safa, Robinson, John L, Xie, Sharon X, Irwin, David J, Roeber, Sigrun, Herms, Jochen, Simons, Mikael, Bartenstein, Peter, Lee, Virginia M, Trojanowski, John Q, Levin, Johannes, Höglinger, Günter, and Ewers, Michael
- Subjects
Biochemistry and Cell Biology ,Biological Sciences ,Acquired Cognitive Impairment ,Rare Diseases ,Brain Disorders ,Pick's Disease ,Alzheimer's Disease ,Dementia ,Frontotemporal Dementia (FTD) ,Neurosciences ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Neurodegenerative ,Aging ,Alzheimer's Disease Related Dementias (ADRD) ,Biomedical Imaging ,Aetiology ,2.1 Biological and endogenous factors ,Neurological ,Brain ,Humans ,Magnetic Resonance Imaging ,Supranuclear Palsy ,Progressive ,Tauopathies ,tau Proteins - Abstract
Tau pathology is the main driver of neuronal dysfunction in 4-repeat tauopathies, including cortico-basal degeneration and progressive supranuclear palsy. Tau is assumed to spread prion-like across connected neurons, but the mechanisms of tau propagation are largely elusive in 4-repeat tauopathies, characterized not only by neuronal but also by astroglial and oligodendroglial tau accumulation. Here, we assess whether connectivity is associated with 4R-tau deposition patterns by combining resting-state fMRI connectomics with both 2nd generation 18F-PI-2620 tau-PET in 46 patients with clinically diagnosed 4-repeat tauopathies and post-mortem cell-type-specific regional tau assessments from two independent progressive supranuclear palsy patient samples (n = 97 and n = 96). We find that inter-regional connectivity is associated with higher inter-regional correlation of both tau-PET and post-mortem tau levels in 4-repeat tauopathies. In regional cell-type specific post-mortem tau assessments, this association is stronger for neuronal than for astroglial or oligodendroglial tau, suggesting that connectivity is primarily associated with neuronal tau accumulation. Using tau-PET we find further that patient-level tau patterns are associated with the connectivity of subcortical tau epicenters. Together, the current study provides combined in vivo tau-PET and histopathological evidence that brain connectivity is associated with tau deposition patterns in 4-repeat tauopathies.
- Published
- 2022
3. BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology
- Author
-
Peters, Finn, Salihoglu, Hazal, Rodrigues, Eva, Herzog, Etienne, Blume, Tanja, Filser, Severin, Dorostkar, Mario, Shimshek, Derya R., Brose, Nils, Neumann, Ulf, and Herms, Jochen
- Published
- 2018
- Full Text
- View/download PDF
4. New Highly Selective BACE1 Inhibitors and Their Effects on Dendritic Spine Density In Vivo.
- Author
-
Pratsch, Katrin, Unemura, Chie, Ito, Mana, Lichtenthaler, Stefan F., Horiguchi, Naotaka, and Herms, Jochen
- Subjects
DENDRITIC spines ,ALZHEIMER'S disease ,SOMATOSENSORY cortex ,NEUROPLASTICITY - Abstract
β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) is considered a therapeutic target to combat Alzheimer's disease by reducing β-amyloid in the brain. To date, all clinical trials involving the inhibition of BACE1 have been discontinued due to a lack of efficacy or undesirable side effects such as cognitive worsening. The latter could have been the result of the inhibition of BACE at the synapse where it is expressed in high amounts. We have previously shown that prolonged inhibition of BACE interferes with structural synaptic plasticity, most likely due to the diminished processing of the physiological BACE substrate Seizure protein 6 (Sez6) which is exclusively processed by BACE1 and is required for dendritic spine plasticity. Given that BACE1 has significant amino acid similarity with its homolog BACE2, the inhibition of BACE2 may cause some of the side effects, as most BACE inhibitors do not discriminate between the two. In this study, we used newly developed BACE inhibitors that have a different chemotype from previously developed inhibitors and a high selectivity for BACE1 over BACE2. By using longitudinal in vivo two-photon microscopy, we investigated the effect on dendritic spine dynamics of pyramidal layer V neurons in the somatosensory cortex in mice treated with highly selective BACE1 inhibitors. Treatment with those inhibitors showed a reduction in soluble Sez6 (sSez6) levels to 27% (elenbecestat, Biogen, Eisai Co., Ltd., Tokyo, Japan), 17% (Shionogi compound 1) and 39% (Shionogi compound 2), compared to animals fed with vehicle pellets. We observed a significant decrease in the number of dendritic spines with Shionogi compound 1 after 21 days of treatment but not with Shionogi compound 2 or with elenbecestat, which did not show cognitive worsening in clinical trials. In conclusion, highly selective BACE1 inhibitors do alter dendritic spine density similar to non-selective inhibitors if soluble (sSez6) levels drop too much. Low-dose BACE1 inhibition might be reasonable if dosing is carefully adjusted to the amount of Sez6 cleavage, which can be easily monitored during the first week of treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. The Trem2 R47H Alzheimer’s risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans
- Author
-
Xiang, Xianyuan, Piers, Thomas M., Wefers, Benedikt, Zhu, Kaichuan, Mallach, Anna, Brunner, Bettina, Kleinberger, Gernot, Song, Wilbur, Colonna, Marco, Herms, Jochen, Wurst, Wolfgang, Pocock, Jennifer M., and Haass, Christian
- Published
- 2018
- Full Text
- View/download PDF
6. Intraneuronal APP and extracellular Aβ independently cause dendritic spine pathology in transgenic mouse models of Alzheimer’s disease
- Author
-
Zou, Chengyu, Montagna, Elena, Shi, Yuan, Peters, Finn, Blazquez-Llorca, Lidia, Shi, Song, Filser, Severin, Dorostkar, Mario M., and Herms, Jochen
- Published
- 2015
- Full Text
- View/download PDF
7. Neurotrophin receptor p75 mediates the uptake of the amyloid beta (Aβ) peptide, guiding it to lysosomes for degradation in basal forebrain cholinergic neurons
- Author
-
Ovsepian, Saak V., Antyborzec, Inga, O’Leary, Valerie B., Zaborszky, Laszlo, Herms, Jochen, and Oliver Dolly, J.
- Published
- 2014
- Full Text
- View/download PDF
8. Single-nucleus chromatin accessibility profiling highlights distinct astrocyte signatures in progressive supranuclear palsy and corticobasal degeneration.
- Author
-
Briel, Nils, Ruf, Viktoria C., Pratsch, Katrin, Roeber, Sigrun, Widmann, Jeannine, Mielke, Janina, Dorostkar, Mario M., Windl, Otto, Arzberger, Thomas, Herms, Jochen, and Struebing, Felix L.
- Subjects
PROGRESSIVE supranuclear palsy ,CHROMATIN ,CELL nuclei ,NEUROFIBRILLARY tangles ,TAUOPATHIES ,ALZHEIMER'S disease ,FRONTAL lobe ,TRANSCRIPTION factors - Abstract
Tauopathies such as progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) exhibit characteristic neuronal and glial inclusions of hyperphosphorylated Tau (pTau). Although the astrocytic pTau phenotype upon neuropathological examination is the most guiding feature in distinguishing both diseases, regulatory mechanisms controlling their transitions into disease-specific states are poorly understood to date. Here, we provide accessible chromatin data of more than 45,000 single nuclei isolated from the frontal cortex of PSP, CBD, and control individuals. We found a strong association of disease-relevant molecular changes with astrocytes and demonstrate that tauopathy-relevant genetic risk variants are tightly linked to astrocytic chromatin accessibility profiles in the brains of PSP and CBD patients. Unlike the established pathogenesis in the secondary tauopathy Alzheimer disease, microglial alterations were relatively sparse. Transcription factor (TF) motif enrichments in pseudotime as well as modeling of the astrocytic TF interplay suggested a common pTau signature for CBD and PSP that is reminiscent of an inflammatory immediate-early response. Nonetheless, machine learning models also predicted discriminatory features, and we observed marked differences in molecular entities related to protein homeostasis between both diseases. Predicted TF involvement was supported by immunofluorescence analyses in postmortem brain tissue for their highly correlated target genes. Collectively, our data expand the current knowledge on risk gene involvement (e.g., MAPT, MAPK8, and NFE2L2) and molecular pathways leading to the phenotypic changes associated with CBD and PSP. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Amyloid plaque formation precedes dendritic spine loss
- Author
-
Bittner, Tobias, Burgold, Steffen, Dorostkar, Mario M., Fuhrmann, Martin, Wegenast-Braun, Bettina M., Schmidt, Boris, Kretzschmar, Hans, and Herms, Jochen
- Published
- 2012
- Full Text
- View/download PDF
10. Role of APP for dendritic spine formation and stability
- Author
-
Jung, Christian K. E. and Herms, Jochen
- Published
- 2012
- Full Text
- View/download PDF
11. In vivo multiphoton imaging reveals gradual growth of newborn amyloid plaques over weeks
- Author
-
Burgold, Steffen, Bittner, Tobias, Dorostkar, Mario M., Kieser, Daniel, Fuhrmann, Martin, Mitteregger, Gerda, Kretzschmar, Hans, Schmidt, Boris, and Herms, Jochen
- Published
- 2011
- Full Text
- View/download PDF
12. Fibrillar Av triggers microglial proteome alterations and dysfunction in Alzheimer mouse models
- Author
-
Monasor, Laura Sebastian, Müller, Stephan A., Colombo, Alessio Vittorio, Tanrioever, Gaye, König, Jasmin, Roth, Stefan, Liesz, Arthur, Berghofer, Anna, Piechotta, Anke, Prestel, Matthias, Saito, Takashi, Saido, Takaomi C., Herms, Jochen, Willem, Michael, Haass, Christian, Lichtenthaler, Stefan F., Tahirovic, Sabina, and Publica
- Subjects
neuroscience ,Neuroinflammation ,Mikroglia ,phagocytosis ,proteomic signature ,Alzheimer's disease ,Maus - Abstract
Microglial dysfunction is a key pathological feature of Alzheimer's disease (AD), but little is known about proteome-wide changes in microglia during the course of AD and their functional consequences. Here, we performed an in-depth and time-resolved proteomic characterization of microglia in two mouse models of amyloid v (Av) pathology, the overexpression APPPS1 and the knock-in APP-NL-G-F (APP-KI) model. We identified a large panel of Microglial Av Response Proteins (MARPs) that reflect heterogeneity of microglial alterations during early, middle and advanced stages of Av deposition and occur earlier in the APPPS1 mice. Strikingly, the kinetic differences in proteomic profiles correlated with the presence of fibrillar Av, rather than dystrophic neurites, suggesting that fibrillar Av may trigger the AD-associated microglial phenotype and the observed functional decline. The identified microglial proteomic fingerprints of AD provide a valuable resource for functional studies of novel molecular targets and potential biomarkers for monitoring AD progression or therapeutic efficacy.
- Published
- 2020
13. In vivo imaging reveals sigmoidal growth kinetic of β-amyloid plaques
- Author
-
Burgold, Steffen, Filser, Severin, Dorostkar, Mario M, Schmidt, Boris, and Herms, Jochen
- Subjects
Male ,metabolism [Amyloid beta-Peptides] ,Plaque, Amyloid ,genetics [Alzheimer Disease] ,Mice, Transgenic ,genetics [Mutation] ,Neuroimaging ,pathology [Alzheimer Disease] ,Mice ,Amyloid beta-Protein Precursor ,PSEN1 protein, human ,Alzheimer Disease ,In vivo ,Presenilin-1 ,Animals ,Humans ,ddc:610 ,pathology [Plaque, Amyloid] ,Two-photon imaging ,Aggregation kinetics ,Amyloid beta-Peptides ,β-amyloid ,Research ,genetics [Presenilin-1] ,metabolism [Plaque, Amyloid] ,Disease Models, Animal ,Kinetics ,genetics [Amyloid beta-Protein Precursor] ,Plaque growth ,Mutation ,Female ,Alzheimer’s disease ,metabolism [Alzheimer Disease] - Abstract
A major neuropathological hallmark of Alzheimer's disease is the deposition of amyloid plaques in the brains of affected individuals. Amyloid plaques mainly consist of fibrillar β-amyloid, which is a cleavage product of the amyloid precursor protein. The amyloid-cascade-hypothesis postulates Aβ accumulation as the central event in initiating a toxic cascade leading to Alzheimer's disease pathology and, ultimately, loss of cognitive function. We studied the kinetics of β-amyloid deposition in Tg2576 mice, which overexpress human amyloid precursor protein with the Swedish mutation. Utilizing long-term two-photon imaging we were able to observe the entire kinetics of plaque growth in vivo. Essentially, we observed that plaque growth follows a sigmoid-shaped curve comprising a cubic growth phase, followed by saturation. In contrast, plaque density kinetics exhibited an asymptotic progression. Taking into account the fact that a critical concentration of Aβ is required to seed new plaques, we can propose the following kinetic model of β-amyloid deposition in vivo. In the early cubic phase, plaque growth is not limited by Aβ concentration and plaque density increases very fast. During the transition phase, plaque density stabilizes whereas plaque volume increases strongly reflecting a robust growth of the plaques. In the late asymptotic phase, Aβ peptide production becomes rate-limiting for plaque growth. In conclusion, the present study offers a direct link between in vitro and in vivo studies facilitating the translation of Aβ-lowering strategies from laboratory models to patients.
- Published
- 2014
14. BACE1 Inhibitor MK-8931 Alters Formation but Not Stability of Dendritic Spines.
- Author
-
Blume, Tanja, Filser, Severin, Jaworska, Anna, Blain, Jean-Francois, Koenig, Gerhard, Moschke, Katrin, Lichtenthaler, Stefan F., and Herms, Jochen
- Subjects
AMYLOID beta-protein precursor ,ALZHEIMER'S disease ,DENDRITIC spines ,MEDICAL sciences ,PATHOGENIC microorganisms - Abstract
Beta-site amyloid-precursor-protein cleaving enzyme 1 (BACE1) is the rate limiting protease in the production of the amyloid-beta peptide (Aβ), which is considered to be the causative agent in the pathogenesis of Alzheimer’s Disease (AD). Therefore, the therapeutic potential of pharmacological BACE1 inhibitors is currently tested in clinical trials for AD treatment. To ensure a positive clinical outcome it is crucial to identify and evaluate adverse effects associated with BACE1 inhibition. Preclinical studies show that chronic blockade of BACE1 activity alters synaptic functions and leads to loss of dendritic spines. To assess the mechanism of synapse loss, dendritic spine dynamics of pyramidal layer V cells were monitored by in vivo two-photon microscopy in the somatosensory cortex of mice, treated with the BACE1 inhibitor MK-8931. MK-8931 treatment significantly reduced levels of Aβ40 and density of dendritic spines in the brain. However, the steady decline in dendritic spine density specifically resulted from a diminished formation of new spines and not from a loss of stable spines. Furthermore, the described effects on spine formation were transient and recovered after inhibitor withdrawal. Since MK-8931 inhibition did not completely abolish spine formation, our findings suggest that carefully dosed inhibitors might be therapeutically effective without affecting the structural integrity of excitatory synapses if given at an early disease stage. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
15. High plasticity of axonal pathology in Alzheimer's disease mouse models.
- Author
-
Blazquez-Llorca, Lidia, Valero-Freitag, Susana, Ferreira Rodrigues, Eva, Merchán-Pérez, Ángel, Rodríguez, J. Rodrigo, Dorostkar, Mario M., DeFelipe, Javier, and Herms, Jochen
- Subjects
PATHOLOGY ,ALZHEIMER'S disease ,MATERIAL plasticity - Abstract
Axonal dystrophies (AxDs) are swollen and tortuous neuronal processes that are associated with extracellular depositions of amyloid β (Aβ) and have been observed to contribute to synaptic alterations occurring in Alzheimer's disease. Understanding the temporal course of this axonal pathology is of high relevance to comprehend the progression of the disease over time. We performed a long-term in vivo study (up to 210 days of two-photon imaging) with two transgenic mouse models (dE9xGFP-M and APP-PS1xGFP-M). Interestingly, AxDs were formed only in a quarter of GFP-expressing axons near Aβ-plaques, which indicates a selective vulnerability. AxDs, especially those reaching larger sizes, had long lifetimes and appeared as highly plastic structures with large variations in size and shape and axonal sprouting over time. In the case of the APP-PS1 mouse only, the formation of new long axonal segments in dystrophic axons (re-growth phenomenon) was observed. Moreover, new AxDs could appear at the same point of the axon where a previous AxD had been located before disappearance (re-formation phenomenon). In addition, we observed that most AxDs were formed and developed during the imaging period, and numerous AxDs had already disappeared by the end of this time. This work is the first in vivo study analyzing quantitatively the high plasticity of the axonal pathology around Aβ plaques. We hypothesized that a therapeutically early prevention of Aβ plaque formation or their growth might halt disease progression and promote functional axon regeneration and the recovery of neural circuits. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
16. Increase of TREM2 during Aging of an Alzheimer's Disease Mouse Model Is Paralleled by Microglial Activation and Amyloidosis.
- Author
-
Brendel, Matthias, Kleinberger, Gernot, Probst, Federico, Jaworska, Anna, Overhoff, Felix, Blume, Tanja, Albert, Nathalie L., Carlsen, Janette, Lindner, Simon, Gildehaus, Franz Josef, Ozmen, Laurence, Suárez-Calvet, Marc, Bartenstein, Peter, Baumann, Karlheinz, Ewers, Michael, Herms, Jochen, Haass, Christian, Rominger, Axel, Gonzalez-Billault, Christian, and Wandosell, Francisco G.
- Subjects
ALZHEIMER'S disease research ,MICROGLIA ,AMYLOIDOSIS ,BRAIN research ,PATHOLOGY - Abstract
Heterozygous missense mutations in the triggering receptor expressed on myeloid cells 2 (TREM2) have been reported to significantly increase the risk of developing Alzheimer's disease (AD). Since TREM2 is specifically expressed by microglia in the brain, we hypothesized that soluble TREM2 (sTREM2) levels may increase together with in vivo biomarkers of microglial activity and amyloidosis in an AD mouse model as assessed by small animal positron-emission-tomography (mPET). In this crosssectional study, we examined a strong amyloid mouse model (PS2APP) of four age groups by mPET with [18F]-GE180 (glial activation) and [18F]-florbetaben (amyloidosis), followed by measurement of sTREM2 levels and amyloid levels in the brain. Pathology affected brain regions were compared between tracers (dice similarity coefficients) and pseudo-longitudinally. mPET results of both tracers were correlated with terminal TREM2 levels. The brain sTREM2 levels strongly increased with age of PS2APP mice (5 vs. 16 months: +211%, p < 0.001), and correlated highly with mPET signals of microglial activity (R = 0.89, p < 0.001) and amyloidosis (R = 0.92, p < 0.001). Dual mPET enabled regional mapping of glial activation and amyloidosis in the mouse brain, which progressed concertedly leading to a high overlap in aged PS2APP mice (dice similarity 67%). Together, these results substantiate the use of in vivo mPET measurements in conjunction with post mortem sTREM2 in future anti-inflammatory treatment trials. Taking human data into account sTREM2 may increase during active amyloid deposition. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
17. Automated Spatial Brain Normalization and Hindbrain White Matter Reference Tissue Give Improved [18F]-Florbetaben PET Quantitation in Alzheimer's Model Mice.
- Author
-
Overhoff, Felix, Brende, Matthias, Jaworska, Anna, Korzhova, Viktoria, Delker, Andreas, Probst, Federico, Fockea, Carola, Gildehaus, Franz-Josef, Carlsen, Janette, Baumann, Karlheinz, Haass, Christian, Bartenstein, Peter, Herms, Jochen, and Rominger, Axel
- Subjects
NEUROSCIENCES ,WHITE matter (Nerve tissue) ,AMYLOID beta-protein - Abstract
Preclinical PET studies of β-amyloid (Ab) accumulation are of growing importance, but comparisons between research sites require standardized and optimized methods for quantitation. Therefore, we aimed to evaluate systematically the (1) impact of an automated algorithm for spatial brain normalization, and (2) intensity scaling methods of different reference regions for Aβ-PET in a large dataset of transgenic mice. PS2APP mice in a 6 week longitudinal setting (N = 37) and another set of PS2APP mice at a histologically assessed narrow range of Aβ burden (N = 40) were investigated by [
18 F]-florbetaben PET. Manual spatial normalization by three readers at different training levels was performed prior to application of an automated brain spatial normalization and inter-reader agreement was assessed by Fleiss Kappa (κ). For this method the impact of templates at different pathology stages was investigated. Four different reference regions on brain uptake normalization were used to calculate frontal cortical standardized uptake value ratios (SUVRCTX/REF ), relative to raw SUVCTX . Results were compared on the basis of longitudinal stability (Cohen's d), and in reference to gold standard histopathological quantitation (Pearson's R). Application of an automated brain spatial normalization resulted in nearly perfect agreement (all κ ⩾ 0.99) between different readers, with constant or improved correlation with histology. Templates based on inappropriate pathology stage resulted in up to 2.9% systematic bias for SUVRCTX/REF . All SUVRCTX/REF methods performed better than SUVCTX both with regard to longitudinal stability (d ⩾ 1.21 vs. d = 0.23) and histological gold standard agreement (R ⩾ 0.66 vs. R ⩾ 0.31). Voxel-wise analysis suggested a physiologically implausible longitudinal decrease by global mean scaling. The hindbrain white matter reference (Rmean = 0.75) was slightly superior to the brainstem (Rmean = 0.74) and the cerebellum (Rmean = 0.73). Automated brain normalization with reference region templates presents an excellent method to avoid the inter-reader variability in preclinical Ab-PET scans. Intracerebral reference regions lacking Ab pathology serve for precise longitudinal in vivo quantification of [18 F]-florbetaben PET. Hindbrain white matter reference performed best when considering the composite of quality criteria. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
18. Fibrillar Amyloid Plaque Formation Precedes Microglial Activation.
- Author
-
Jung, Christian K. E., Keppler, Kevin, Steinbach, Sonja, Blazquez-Llorca, Lidia, and Herms, Jochen
- Subjects
ALZHEIMER'S disease ,AMYLOID plaque ,FIBRILLARIN ,MICROGLIA ,ENZYME activation - Abstract
In Alzheimer’s disease (AD), hallmark β-amyloid deposits are characterized by the presence of activated microglia around them. Despite an extensive characterization of the relation of amyloid plaques with microglia, little is known about the initiation of this interaction. In this study, the detailed investigation of very small plaques in brain slices in AD transgenic mice of the line APP-PS1(dE9) revealed different levels of microglia recruitment. Analysing plaques with a diameter of up to 10 μm we find that only the half are associated with clear morphologically activated microglia. Utilizing in vivo imaging of new appearing amyloid plaques in double-transgenic APP-PS1(dE9)xCX3CR1
+/- mice further characterized the dynamic of morphological microglia activation. We observed no correlation of morphological microglia activation and plaque volume or plaque lifetime. Taken together, our results demonstrate a very prominent variation in size as well as in lifetime of new plaques relative to the state of microglia reaction. These observations might question the existing view that amyloid deposits by themselves are sufficient to attract and activate microglia in vivo. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
19. Cross-Sectional Comparison of Small Animal [18F]-Florbetaben Amyloid-PET between Transgenic AD Mouse Models.
- Author
-
Brendel, Matthias, Jaworska, Anna, Grießinger, Eric, Rötzer, Christina, Burgold, Steffen, Gildehaus, Franz-Josef, Carlsen, Janette, Cumming, Paul, Baumann, Karlheinz, Haass, Christian, Steiner, Harald, Bartenstein, Peter, Herms, Jochen, and Rominger, Axel
- Subjects
AMYLOID beta-protein ,POSITRON emission tomography ,LABORATORY mice ,ALZHEIMER'S disease ,AUTORADIOGRAPHY - Abstract
We aimed to compare [
18 F]-florbetaben PET imaging in four transgenic mouse strains modelling Alzheimer’s disease (AD), with the main focus on APPswe/PS2 mice and C57Bl/6 mice serving as controls (WT). A consistent PET protocol (N = 82 PET scans) was used, with cortical standardized uptake value ratio (SUVR) relative to cerebellum as the endpoint. We correlated methoxy-X04 staining of β-amyloid with PET results, and undertook ex vivo autoradiography for further validation of a partial volume effect correction (PVEC) of PET data. The SUVR in APPswe/PS2 increased from 0.95±0.04 at five months (N = 5) and 1.04±0.03 (p<0.05) at eight months (N = 7) to 1.07±0.04 (p<0.005) at ten months (N = 6), 1.28±0.06 (p<0.001) at 16 months (N = 6) and 1.39±0.09 (p<0.001) at 19 months (N = 6). SUVR was 0.95±0.03 in WT mice of all ages (N = 22). In APPswe/PS1G384A mice, the SUVR was 0.93/0.98 at five months (N = 2) and 1.11 at 16 months (N = 1). In APPswe/PS1dE9 mice, the SUVR declined from 0.96/0.96 at 12 months (N = 2) to 0.91/0.92 at 24 months (N = 2), due to β-amyloid plaques in cerebellum. PVEC reduced the discrepancy between SUVR-PET and autoradiography from −22% to +2% and increased the differences between young and aged transgenic animals. SUVR and plaque load correlated highly between strains for uncorrected (R = 0.94, p<0.001) and PVE-corrected (R = 0.95, p<0.001) data. We find that APPswe/PS2 mice may be optimal for longitudinal amyloid-PET monitoring in planned interventions studies. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
20. Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer’s disease mouse model.
- Author
-
Dorostkar, Mario M., Burgold, Steffen, Filser, Severin, Barghorn, Stefan, Schmidt, Boris, Anumala, Upendra Rao, Hillen, Heinz, Klein, Corinna, and Herms, Jochen
- Subjects
IMMUNOTHERAPY ,ALZHEIMER'S disease ,LABORATORY mice ,AMYLOID beta-protein ,OLIGOMERS ,IMMUNOHISTOCHEMISTRY - Abstract
Accumulation of amyloid-beta leads to loss of functional synapses in Alzheimer’s disease. Dorostkar et al. report that immunotherapy against oligomeric amyloid-beta in the Tg2576 mouse model attenuates synapse loss near plaques, and abolishes it elsewhere. Sequestering oligomeric amyloid-beta may counteract synaptic pathology, even while fibrillar amyloid load remains unchanged.Cognitive decline in Alzheimer’s disease is attributed to loss of functional synapses, most likely caused by synaptotoxic, oligomeric forms of amyloid-β. Many treatment options aim at reducing amyloid-β levels in the brain, either by decreasing its production or by increasing its clearance. We quantified the effects of immunotherapy directed against oligomeric amyloid-β in Tg2576 mice, a mouse model of familial Alzheimer’s disease. Treatment of 12-month-old mice with oligomer-specific (A-887755) or conformation-unspecific (6G1) antibodies for 8 weeks did not affect fibrillar plaque density or growth. We also quantified densities of DLG4 (previously known as PSD95) expressing post-synapses and synapsin expressing presynapses immunohistochemically. We found that both pre- and post-synapses were strongly reduced in the vicinity of plaques, whereas distant from plaques, in the cortex and hippocampal CA1 field, only post-synapses were reduced. Immunotherapy alleviated this synapse loss. Synapse loss was completely abolished distant from plaques, whereas it was only attenuated in the vicinity of plaques. These results suggest that fibrillar plaques may act as reservoirs for synaptotoxic, oligomeric amyloid-β and that sequestering oligomers suffices to counteract synaptic pathology. Therefore, cognitive function may be improved by immunotherapy even when the load of fibrillar amyloid remains unchanged. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
21. Drain of the brain: low-affinity p75 neurotrophin receptor affords a molecular sink for clearance of cortical amyloid β by the cholinergic modulator system.
- Author
-
Ovsepian, Saak V. and Herms, Jochen
- Subjects
- *
NEUROTROPHIN receptors , *AMYLOID beta-protein , *BRAIN anatomy , *CHOLINERGIC mechanisms , *ACETYLCHOLINE ,AGE factors in Alzheimer's disease - Abstract
Abstract: Cholinergic basal forebrain (BF) neurons source one of the largest modulator systems of the brain, supplying acetylcholine to the entire cerebral mantle. Ample evidence suggests a causal link between the depletion of cortical acetylcholine and the selective disruption of cognitive functions in the course of aging and Alzheimer's disease (AD). A distinctive yet underappreciated feature of BF cholinergic neurons is their enrichment with the p75 neurotrophin receptor (p75NTR), which is also recognized as a high-affinity acceptor for the amyloid-β (Aβ) peptide. Herein, we critically overview the emerging data, which suggest the relevance of p75NTR-mediated uptake of Aβ followed by its degradation in lysosomes of BF cholinergic neurons for the homeostasis and clearance of this peptide from the cerebral cortex. We propose that via such a unique arrangement, cholinergic neurons afford their functional targets with an efficient molecular “drain” for Aβ. This process is suggested as the proximal cause for the greater “wear and tear” of the BF cholinergic system during aging and especially AD. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
22. Involvement of presenilin holoprotein upregulation in calcium dyshomeostasis of Alzheimer's disease.
- Author
-
Honarnejad, Kamran, Jung, Christian K.E., Lammich, Sven, Arzberger, Thomas, Kretzschmar, Hans, and Herms, Jochen
- Subjects
PRESENILINS ,GENETIC regulation ,HOMEOSTASIS ,CALCIUM in the body ,ALZHEIMER'S disease ,GENETIC mutation ,GENE expression - Abstract
Mutations in presenilins ( PS1 and PS2) account for the vast majority of early onset familial Alzheimer's disease cases. Beside the well investigated role of presenilins as the catalytic unit in γ-secretase complex, their involvement in regulation of intracellular calcium homeostasis has recently come into more focus of Alzheimer's disease research. Here we report that the overexpression of PS1 full-length holoprotein forms, in particular familial Alzheimer's disease-causing forms of PS1, result in significantly attenuated calcium release from thapsigargin- and bradykinin-sensitive stores. Interestingly, treatment of HEK293 cells with γ-secretase inhibitors also leads to decreased amount of calcium release from endoplasmic reticulum (ER) accompanying elevated PS1 holoprotein levels. Similarly, the knockdown of PEN-2 which is associated with deficient PS1 endoproteolysis and accumulation of its holoprotein form also leads to decreased ER calcium release. Notably, we detected enhanced PS1 holoprotein levels also in postmortem brains of patients carrying familial Alzheimer's disease PS1 mutations. Taken together, the conditions in which the amount of full length PS1 holoprotein is increased result in reduction of calcium release from ER. Based on these results, we propose that the disturbed ER calcium homeostasis mediated by the elevation of PS1 holoprotein levels may be a contributing factor to the pathogenesis of Alzheimer's disease. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
23. Long-Term In Vivo Imaging of Fibrillar Tau in the Retina of P301S Transgenic Mice.
- Author
-
Schön, Christian, Hoffmann, Nadine A., Ochs, Simon M., Burgold, Steffen, Filser, Severin, Steinbach, Sonja, W.^Seeliger, Mathias, Arzberger, Thomas, Goedert, Michel, A.^Kretzschmar, Hans, Schmidt, Boris, and Herms, Jochen
- Subjects
TAU proteins ,CHRONIC traumatic encephalopathy ,RETINAL diseases ,TRANSGENIC mice ,ALZHEIMER'S disease - Abstract
Tauopathies are widespread neurodegenerative disorders characterised by the intracellular accumulation of hyperphosphorylated tau. Especially in Alzheimer's disease, pathological alterations in the retina are discussed as potential biomarkers to improve early diagnosis of the disease. Using mice expressing human mutant P301S tau, we demonstrate for the first time a straightforward optical approach for the in vivo detection of fibrillar tau in the retina. Longitudinal examinations of individual animals revealed the fate of single cells containing fibrillar tau and the progression of tau pathology over several months. This technique is most suitable to monitor therapeutic interventions aimed at reducing the accumulation of fibrillar tau. In order to evaluate if this approach can be translated to human diagnosis, we tried to detect fibrillar protein aggregates in the post-mortem retinas of patients that had suffered from Alzheimer's disease or Progressive Supranuclear Palsy. Even though we could detect hyperphosphorylated tau, we did not observe any fibrillar tau or Aß aggregates. In contradiction to previous studies, our observations do not support the notion that Aβ or tau in the retina are of diagnostic value in Alzheimer's disease. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
24. Presenilins: Role in calcium homeostasis
- Author
-
Honarnejad, Kamran and Herms, Jochen
- Subjects
- *
PRESENILINS , *HOMEOSTASIS , *GENETIC mutation , *ETIOLOGY of Alzheimer's disease , *AMYLOID beta-protein precursor , *C-terminal binding proteins , *ENDOPLASMIC reticulum - Abstract
Abstract: Mutations in presenilins are responsible for the vast majority of early-onset familial Alzheimer''s disease cases. Full-length presenilin structure is composed of nine transmembrane domains which are localized on the endoplasmic reticulum membrane. Upon endoproteolytic cleavage, presenilins assemble into the γ-secretase multiprotein complex and subsequently get transported to the cell surface. There is a wealth of knowledge around the role of presenilins as the catalytic component of γ-secretase, their involvement in amyloid precursor protein processing and generation of neurotoxic β-amyloid species. However recent findings have revealed a wide range of γ-secretase-independent presenilin functions, including involvement in calcium homeostasis. Particularly, familial Alzheimer''s disease presenilin mutations have been shown to interfere with the function of several molecular elements involved in endoplasmic reticulum calcium homeostasis. Presenilins modulate the activity of IP3 and Ryanodine receptor channels, regulate SERCA pump function, affect capacitative calcium entry and function per se as endoplasmic reticulum calcium leak conductance pores. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
25. Role of presenilin1 in structural plasticity of cortical dendritic spines in vivo.
- Author
-
Jung, Christian K. E., Fuhrmann, Martin, Honarnejad, Kamran, Van Leuven, Fred, and Herms, Jochen
- Subjects
PRESENILINS ,NEUROPLASTICITY ,ALZHEIMER'S disease ,NEURODEGENERATION ,TRANSGENE expression ,NEUROCHEMISTRY - Abstract
J. Neurochem. (2011) 119, 1064-1073. Abstract Mutations in presenilins are the major cause of familial Alzheimer's disease (FAD), leading to impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Presenilins are the catalytic subunits of γ-secretase, which itself is critically involved in the processing of amyloid precursor protein to release neurotoxic amyloid β (Aβ). Besides Aβ generation, there is growing evidence that presenilins play an essential role in the formation and maintenance of synapses. To further elucidate the effect of presenilin1 (PS1) on synapses, we performed longitudinal in vivo two-photon imaging of dendritic spines in the somatosensory cortex of transgenic mice over-expressing either human wild-type PS1 or the FAD-mutated variant A246E (FAD-PS1). Interestingly, the consequences of transgene expression were different in two subtypes of cortical dendrites. On apical layer 5 dendrites, we found an enhanced spine density in both mice over-expressing human wild-type presenilin1 and FAD-PS1, whereas on basal layer 3 dendrites only over-expression of FAD-PS1 increased the spine density. Time-lapse imaging revealed no differences in kinetically distinct classes of dendritic spines nor was the shape of spines affected. Although γ-secretase-dependent processing of synapse-relevant proteins seemed to be unaltered, higher expression levels of ryanodine receptors suggest a modified Ca
2+ homeostasis in PS1 over-expressing mice. However, the conditional depletion of PS1 in single cortical neurons had no observable impact on dendritic spines. In consequence, our results favor the view that PS1 influences dendritic spine plasticity in a gain-of-function but γ-secretase-independent manner. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
26. Multiple Events Lead to Dendritic Spine Loss in Triple Transgenic Alzheimer's Disease Mice.
- Author
-
Bittner, Tobias, Fuhrmann, Martin, Burgold, Steffen, Ochs, Simon M., Hoffmann, Nadine, Mitteregger, Gerda, Kretzschmar, Hans, LaFerla, Frank M., and Herms, Jochen
- Subjects
TRANSGENIC mice ,ALZHEIMER'S disease ,AMYLOID ,DENDRITIC cells ,LABORATORY mice ,NEURONS ,DISEASES - Abstract
The pathology of Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β (Aβ) peptide, hyperphosphorylated tau protein, neuronal death, and synaptic loss. By means of long-term two-photon in vivo imaging and confocal imaging, we characterized the spatio-temporal pattern of dendritic spine loss for the first time in 3xTg-AD mice. These mice exhibit an early loss of layer III neurons at 4 months of age, at a time when only soluble Aβ is abundant. Later on, dendritic spines are lost around amyloid plaques once they appear at 13 months of age. At the same age, we observed spine loss also in areas apart from amyloid plaques. This plaque independent spine loss manifests exclusively at dystrophic dendrites that accumulate both soluble Aβ and hyperphosphorylated tau intracellularly. Collectively, our data shows that three spatiotemporally independent events contribute to a net loss of dendritic spines. These events coincided either with the occurrence of intracellular soluble or extracellular fibrillar Aβ alone, or the combination of intracellular soluble Aβ and hyperphosphorylated tau. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
27. Bepridil and Amiodarone Simultaneously Target the Alzheimer's Disease β- and γ-Secretase via Distinct Mechanisms.
- Author
-
Mitterreiter, Stefan, Page, Richard M., Kamp, Frits, Hopson, Jessika, Winkler, Edith, Huy-Riem Ha, Hamid, Runa, Herms, Jochen, Mayer, Thomas U., Nelson, Deborah J., Steiner, Harald, Stahl, Tobias, Zeitschel, Ulrike, Roßner, Steffen, Haass, Christian, and Lichtenthaler, Stefan F.
- Subjects
PROTEOLYTIC enzymes ,AMYLOID beta-protein ,ALZHEIMER'S disease ,ENDOSOMES ,AMIODARONE ,CALCIUM antagonists - Abstract
The two proteases β-secretase and γ-secretase generate the amyloid β peptide and are drug targets for Alzheimer's disease. Here we tested the possibility of targeting the cellular environment of β-secretase cleavage instead of the β-secretase enzyme itself. β-Secretase has an acidic pH optimum and cleaves the amyloid precursor protein in the acidic endosomes. We identified two drugs, bepridil and amiodarone, that are weak bases and are in clinical use as calcium antagonists. Independently of their calcium-blocking activity, both compounds mildly raised the membrane-proximal, endosomal pH and inhibited β-secretase cleavage at therapeutically achievable concentrations in cultured cells, in primary neurons, and in vivo in guinea pigs. This shows that an alkalinization of the cellular environment could be a novel therapeutic strategy to inhibit β-secretase. Surprisingly, bepridil and amiodarone also modulated γ-secretase cleavage independently of endosomal alkalinization. Thus, both compounds act as dual modulators that simultaneously target β- and γ-secretase through distinct molecular mechanisms. In addition to Alzheimer's disease, compounds with dual properties may also be useful for drug development targeting other membrane proteins. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
28. γ-Secretase Inhibition Reduces Spine Density In Vivo via an Amyloid Precursor Protein-Dependent Pathway.
- Author
-
Bittner, Tobias, Fuhrmann, Martin, Burgold, Steffen, Jung, Christian K. E., Volbracht, Christiane, Steiner, Harald, Mitteregger, Gerda, Kretzschmar, Hans A., Haass, Christian, and Herms, Jochen
- Subjects
ALZHEIMER'S disease ,PRESENILE dementia ,NEURODEGENERATION ,COGNITION disorders ,THERAPEUTICS ,LABORATORY mice - Abstract
Alzheimer's disease (AD) represents the most common age-related neurodegenerative disorder. It is characterized by the invariant accumulation of the β-amyloid peptide (Aβ), which mediates synapse loss and cognitive impairment in AD. Current therapeutic approaches concentrate on reducing Aβ levels and amyloid plaque load via modifying or inhibiting the generation of Aβ. Based on in vivo two-photon imaging, we present evidence that side effects on the level of dendritic spines may counteract the beneficial potential of these approaches. Two potent γ-secretase inhibitors (GSIs), DAPT (N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester) and LY450139 (hydroxylvaleryl monobenzocaprolactam), were found to reduce the density of dendritic spines in wild-type mice. In mice deficient for the amyloid precursor protein (APP), both GSIs had no effect on dendritic spine density, demonstrating that γ-secretase inhibition decreases dendritic spine density via APP. Independent of the effects of γ-secretase inhibition, we observed a twofold higher density of dendritic spines in the cerebral cortex of adult APP-deficient mice. This observation further supports the notion that APP is involved in the modulation of dendritic spine density—shown here for the first time in vivo. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
29. Calcium dysregulation in Alzheimer's disease
- Author
-
Bojarski, Lukasz, Herms, Jochen, and Kuznicki, Jacek
- Subjects
- *
ALZHEIMER'S disease , *GLYCOPROTEINS , *HUNTINGTON disease , *PHYSIOLOGICAL control systems - Abstract
Abstract: Alzheimer disease (AD) is the most common form of adult dementia. Its pathological hallmarks are synaptic degeneration, deposition of amyloid plaques and neurofibrillary tangles, leading to neuronal loss. A few hypotheses have been proposed to explain AD pathogenesis. The beta-amyloid (Aβ) and hyperphosphorylated tau hypotheses suggest that these proteins are the main players in AD development. Another hypothesis proposes that the dysregulation of calcium homeostasis may be a key factor in accelerating other pathological changes. Although Aβ and tau have been extensively studied, recently published data provide a growing body of evidence supporting the critical role of calcium signalling in AD. For example, presenilins, which are mutated in familial cases of AD, were demonstrated to form low conductance calcium channels in the ER and elevated cytosolic calcium concentration increases amyloid generation. Moreover, memantine, an antagonist of the NMDA-calcium channel receptor, has been found to have a beneficial effect for AD patients offering novel possibilities for a calcium signalling targeted therapy of AD. This review underscores the growing importance of calcium ions in AD development and focuses on the relevant aspects of calcium homeostasis. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
30. Amyloid precursor protein intracellular domain modulates cellular calcium homeostasis and ATP content.
- Author
-
Hamid, Runa, Kilger, Ellen, Willem, Michael, Vassallo, Neville, Kostka, Markus, Bornhövd, Carsten, Reichert, Andreas S., Kretzschmar, Hans A., Haass, Christian, and Herms, Jochen
- Subjects
HOMEOSTASIS ,CALCIUM ,ADENOSINE triphosphate ,AMYLOID ,PHYSIOLOGICAL control systems ,GLYCOPROTEINS - Abstract
Consecutive cleavages of amyloid precursor protein (APP) generate APP intracellular domain (AICD). Its cellular function is still unclear. In this study, we investigated the functional role of AICD in cellular Ca
2+ homeostasis. We could confirm previous observations that endoplasmic reticulum Ca2+ stores contain less calcium in cells with reduced APP γ-secretase cleavage products, increased AICD degradation, reduced AICD expression or in cells lacking APP. In addition, we observed an enhanced resting cytosolic calcium concentration under conditions where AICD is decreased or missing. In view of the reciprocal effects of Ca2+ on mitochondria and of mitochondria on Ca2+ homeostasis, we analysed further the cellular ATP content and the mitochondrial membrane potential. We observed a reduced ATP content and a mitochondrial hyperpolarisation in cells with reduced amounts of AICD. Blockade of mitochondrial oxidative phosphorylation chain in control cells lead to similar alterations as in cells lacking AICD. On the other hand, substrates of Complex II rescued the alteration in Ca2+ homeostasis in cells lacking AICD. Based on these observations, our findings indicate that alterations observed in endoplasmic reticulum Ca2+ storage in cells with reduced amounts of AICD are reciprocally linked to mitochondrial bioenergetic function. [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
31. The Secreted β-Amyloid Precursor Protein Ectodomain APPsα Is Sufficient to Rescue the Anatomical, Behavioral, and Electrophysiological Abnormalities of APP-Deficient Mice.
- Author
-
Ring, Sabine, Weyer, Sascha W., Kilian, Susanne B., Waldron, Elaine, Pietrzik, Claus U., Filippov, Mikhail A., Herms, Jochen, Buchholz, Christian, Eckman, Christopher B., Korte, Martin, Wolfer, David P., and Müller, Ulrike C.
- Subjects
AMYLOID beta-protein precursor ,ALZHEIMER'S disease ,ELECTROPHYSIOLOGY ,CELL membranes ,MICE behavior - Abstract
It is well established that the proteolytic processing of the β-amyloid precursor protein (APP) generates β-amyloid (Aβ), which plays a central role in the pathogenesis of Alzheimer's disease (AD). In contrast, the physiological role of APP and of its numerous proteolytic fragments and the question of whether a loss of these functions contributes to AD are still unknown. To address this question, we replaced the endogenous APP locus by gene-targeted alleles and generated two lines of knock-in mice that exclusively express APP deletion variants corresponding either to the secreted APP ectodomain (APPsα) or to a C-terminal (CT) truncation lacking the YENPTY interaction motif (APPΔCT15). Interestingly, the ΔCT15 deletion resulted in reduced turnover of holoAPP, increased cell surface expression, and strongly reduced Aβ levels in brain, likely because of reduced processing in the endocytic pathway. Most importantly, we demonstrate that in both APP knock-in lines the expression of APP N-terminal domains either grossly attenuated or completely rescued the prominent deficits of APP knock-out mice, such as reductions in brain and body weight, grip strength deficits, alterations in circadian locomotor activity, exploratory activity, and the impairment in spatial learning and long-term potentiation. Together, our data suggest that the APP C terminus is dispensable and that APPsα is sufficient to mediate the physiological functions of APP assessed by these tests. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
32. Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members.
- Author
-
Herms, Jochen, Anliker, Brigitte, Heber, Sabine, Ring, Sabine, Fuhrmann, Martin, Kretzschmar, Hans, Sisodia, Sangram, and Müller, Ulrike
- Subjects
- *
DYSPLASIA , *LISSENCEPHALY , *LABORATORY mice , *AMYLOID beta-protein precursor , *EMBRYOLOGY , *ALZHEIMER'S disease - Abstract
The Alzheimer's diseaseß-amyloid precursor protein (APP) is a member of a larger gene family that includes the amyloid precursor-like proteins, termed APLP1 and APLP2. We previously documented that APLP2-/-APLP1-/- and APLP2-/-APP-/- mice die postnatally, while APLP1-/-APP-/- mice and single mutants were viable. We now report that mice lacking all three APP/APLP family members survive through embryonic development, and die shortly after birth. In contrast to double-mutant animals with perinatal lethality, 81%of triple mutants showed cranial abnormalities. In 68%of triple mutants, we observed cortical dysplasias characterized by focal ectopic neuroblasts that had migrated through the basal lamina and pial membrane, a phenotype that resembles human type II lissencephaly. Moreover, at E18.5 triple mutants showed a partial loss of cortical Cajal Retzius (CR) cells, suggesting that APP/APLPs play a crucial role in the survival of CR cells and neuronal adhesion. Collectively, our data reveal an essential role for APP family members in normal brain development and early postnatal survival. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
33. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease.
- Author
-
Fuhrmann, Martin, Bittner, Tobias, Jung, Christian K. E., Burgold, Steffen, Page, Richard M., Mitteregger, Gerda, Haass, Christian, LaFerla, Frank M., Kretzschmar, Hans, and Herms, Jochen
- Subjects
ALZHEIMER'S disease ,MICROGLIA ,BRAIN ,NEURODEGENERATION ,PHAGOCYTES - Abstract
Microglia, the immune cells of the brain, can have a beneficial effect in Alzheimer's disease by phagocytosing amyloid-β. Two-photon in vivo imaging of neuron loss in the intact brain of living Alzheimer's disease mice revealed an involvement of microglia in neuron elimination, indicated by locally increased number and migration velocity of microglia around lost neurons. Knockout of the microglial chemokine receptor Cx3cr1, which is critical in neuron-microglia communication, prevented neuron loss. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
34. Tau deletion reduces plaque‐associated BACE1 accumulation and decelerates plaque formation in a mouse model of Alzheimer's disease.
- Author
-
Peters, Finn, Salihoglu, Hazal, Pratsch, Katrin, Herzog, Etienne, Pigoni, Martina, Sgobio, Carmelo, Lichtenthaler, Stefan F, Neumann, Ulf, and Herms, Jochen
- Subjects
TAU proteins ,ALZHEIMER'S disease ,AMYLOID beta-protein precursor ,CARRIER proteins ,MICROTUBULE-associated proteins ,AXONAL transport - Abstract
In Alzheimer's disease, BACE1 protease initiates the amyloidogenic processing of amyloid precursor protein (APP) that eventually results in synthesis of β‐amyloid (Aβ) peptide. Aβ deposition in turn causes accumulation of BACE1 in plaque‐associated dystrophic neurites, thereby potentiating progressive Aβ deposition once initiated. Since systemic pharmacological BACE inhibition causes adverse effects in humans, it is important to identify strategies that specifically normalize overt BACE1 activity around plaques. The microtubule‐associated protein tau regulates axonal transport of proteins, and tau deletion rescues Aβ‐induced transport deficits in vitro. In the current study, long‐term in vivo two‐photon microscopy and immunohistochemistry were performed in tau‐deficient APPPS1 mice. Tau deletion reduced plaque‐associated axonal pathology and BACE1 accumulation without affecting physiological BACE1 expression distant from plaques. Thereby, tau deletion effectively decelerated formation of new plaques and reduced plaque compactness. The data revealed that tau reinforces Aβ deposition, presumably by contributing to accumulation of BACE1 in plaque‐associated dystrophies. Targeting tau‐dependent mechanisms could become a suitable strategy to specifically reduce overt BACE1 activity around plaques, thereby avoiding adverse effects of systemic BACE inhibition. Synopsis: Tau deletion reduces overt accumulation of BACE1 associated with progressive Aβ deposition. Tau‐targeted therapy emerges as an alternative strategy to normalize BACE1 expression and thus avoid systemic inhibition of physiological BACE activity. Tau deletion alleviates overt accumulation of BACE1 and APP around plaques.Tau deletion reduces plaque‐associated axonal pathology.Tau deletion attenuates plaque formation.Tau deletion reduces plaque compactness. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
35. Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau.
- Author
-
Brendel, Matthias, Deussing, Maximilian, Blume, Tanja, Kaiser, Lena, Probst, Federico, Overhoff, Felix, Peters, Finn, von Ungern-Sternberg, Barbara, Ryazanov, Sergey, Leonov, Andrei, Griesinger, Christian, Zwergal, Andreas, Levin, Johannes, Bartenstein, Peter, Yakushev, Igor, Cumming, Paul, Boening, Guido, Ziegler, Sibylle, Herms, Jochen, and Giese, Armin
- Subjects
TAU proteins ,ALZHEIMER'S disease ,THERAPEUTICS ,POSITRON emission tomography ,TRANSGENIC mice ,GLUCOSE metabolism - Abstract
Background: Augmenting the brain clearance of toxic oligomers with small molecule modulators constitutes a promising therapeutic concept against tau deposition. However, there has been no test of this concept in animal models of Alzheimer's disease (AD) with initiation at a late disease stage. Thus, we aimed to investigate the effects of interventional late-stage Anle138b treatment, which previously indicated great potential to inhibit oligomer accumulation by binding of pathological aggregates, on the metabolic decline in transgenic mice with established tauopathy in a longitudinal
18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) study. Methods: Twelve transgenic mice expressing all six human tau isoforms (hTau) and ten controls were imaged by FDG-PET at baseline (14.5 months), followed by randomization into Anle138b treatment and vehicle groups for 3 months. FDG-PET was repeated after treatment for 3 months, and brains were analyzed by tau immunohistochemistry. Longitudinal changes of glucose metabolism were compared between study groups, and the end point tau load was correlated with individual FDG-PET findings. Results: Tau pathology was significantly ameliorated by late-stage Anle138b treatment when compared to vehicle (frontal cortex − 53%, p < 0.001; hippocampus − 59%, p < 0.005). FDG-PET revealed a reversal of metabolic decline during Anle138b treatment, whereas the vehicle group showed ongoing deterioration. End point glucose metabolism in the brain of hTau mice had a strong correlation with tau deposition measured by immunohistochemistry (R = 0.92, p < 0.001). Conclusion: Late-stage oligomer modulation effectively ameliorated tau pathology in hTau mice and rescued metabolic function. Molecular imaging by FDG-PET can serve for monitoring effects of Anle138b treatment. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
36. Microglial response to increasing amyloid load saturates with aging: a longitudinal dual tracer in vivo μPET-study.
- Author
-
Blume, Tanja, Focke, Carola, Peters, Finn, Deussing, Maximilian, Albert, Nathalie L., Lindner, Simon, Gildehaus, Franz-Josef, von Ungern-Sternberg, Barbara, Ozmen, Laurence, Baumann, Karlheinz, Bartenstein, Peter, Rominger, Axel, Herms, Jochen, and Brendel, Matthias
- Subjects
AMYLOID ,MICROGLIA ,ALZHEIMER'S disease ,DISEASE progression ,TRANSLOCATOR proteins - Abstract
Background: Causal associations between microglia activation and β-amyloid (Aβ) accumulation during the progression of Alzheimer's disease (AD) remain a matter of controversy. Therefore, we used longitudinal dual tracer in vivo small animal positron emission tomography (μPET) imaging to resolve the progression of the association between Aβ deposition and microglial responses during aging of an Aβ mouse model.Methods: APP-SL70 mice (N = 17; baseline age 3.2-8.5 months) and age-matched C57Bl/6 controls (wildtype (wt)) were investigated longitudinally for 6 months using Aβ (18F-florbetaben) and 18 kDa translocator protein (TSPO) μPET (18F-GE180). Changes in cortical binding were transformed to Z-scores relative to wt mice, and microglial activation relative to amyloidosis was defined as the Z-score difference (TSPO-Aβ). Using 3D immunohistochemistry for activated microglia (Iba-1) and histology for fibrillary Aβ (methoxy-X04), we measure microglial brain fraction relative to plaque size and the distance from plaque margins.Results: Aβ-PET binding increased exponentially as a function of age in APP-SL70 mice, whereas TSPO binding had an inverse U-shape growth function. Longitudinal Z-score differences declined with aging, suggesting that microglial response declined relative to increasing amyloidosis in aging APP-SL70 mice. Microglial brain volume fraction was inversely related to adjacent plaque size, while the proximity to Aβ plaques increased with age.Conclusions: Microglial activity decreases relative to ongoing amyloidosis with aging in APP-SL70 mice. The plaque-associated microglial brain fraction saturated and correlated negatively with increasing plaque size with aging. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
37. High plasticity of axonal pathology in Alzheimer’s disease mouse models
- Author
-
Blazquez-Llorca, Lidia, Valero-Freitag, Susana, Rodrigues, Eva Ferreira, Merchán-Pérez, Ángel, Rodríguez, J. Rodrigo, Dorostkar, Mario M., DeFelipe, Javier, Herms, Jochen, Ministerio de Economía y Competitividad (España), Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (España), Alzheimer's Association, and Alexander von Humboldt Foundation
- Subjects
Green Fluorescent Proteins ,Plaque, Amyloid ,Mice, Transgenic ,metabolism [Axons] ,Dystrophic neurites ,APP protein, human ,pathology [Alzheimer Disease] ,Amyloid beta-Protein Precursor ,PSEN1 protein, human ,Imaging, Three-Dimensional ,Microscopy, Electron, Transmission ,Alzheimer Disease ,metabolism [Amyloid beta-Protein Precursor] ,Presenilin-1 ,Animals ,genetics [Green Fluorescent Proteins] ,Humans ,ddc:610 ,pathology [Plaque, Amyloid] ,Two-photon microscopy ,Cell Size ,Neuronal Plasticity ,pathology [Axons] ,metabolism [Presenilin-1] ,Research ,Somatosensory Cortex ,genetics [Presenilin-1] ,pathology [Somatosensory Cortex] ,FIB/SEM microscopy ,Axons ,metabolism [Plaque, Amyloid] ,Disease Models, Animal ,Microscopy, Fluorescence ,nervous system ,genetics [Amyloid beta-Protein Precursor] ,metabolism [Green Fluorescent Proteins] ,Microscopy, Electron, Scanning ,metabolism [Somatosensory Cortex] ,Three-dimensional ,Alzheimer’s disease ,metabolism [Alzheimer Disease] - Abstract
© The Author(s)., Axonal dystrophies (AxDs) are swollen and tortuous neuronal processes that are associated with extracellular depositions of amyloid β (Aβ) and have been observed to contribute to synaptic alterations occurring in Alzheimer’s disease. Understanding the temporal course of this axonal pathology is of high relevance to comprehend the progression of the disease over time. We performed a long-term in vivo study (up to 210 days of two-photon imaging) with two transgenic mouse models (dE9xGFP-M and APP-PS1xGFP-M). Interestingly, AxDs were formed only in a quarter of GFP-expressing axons near Aβ-plaques, which indicates a selective vulnerability. AxDs, especially those reaching larger sizes, had long lifetimes and appeared as highly plastic structures with large variations in size and shape and axonal sprouting over time. In the case of the APP-PS1 mouse only, the formation of new long axonal segments in dystrophic axons (re-growth phenomenon) was observed. Moreover, new AxDs could appear at the same point of the axon where a previous AxD had been located before disappearance (re-formation phenomenon). In addition, we observed that most AxDs were formed and developed during the imaging period, and numerous AxDs had already disappeared by the end of this time. This work is the first in vivo study analyzing quantitatively the high plasticity of the axonal pathology around Aβ plaques. We hypothesized that a therapeutically early prevention of Aβ plaque formation or their growth might halt disease progression and promote functional axon regeneration and the recovery of neural circuits., The work was supported by grants from the Spanish Ministry of Economy and Competitiveness (MINECO) (BFU2012-34963 to JF), the Centre for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED, CB06/05/0066) (to JF), a grant from the Alzheimer’s Association (ZEN-15-321663) (to JF) and the Humboldt Research Fellowship for Postdoctoral Researchers (LBL).
- Full Text
- View/download PDF
38. Synapse Formation and Function Is Modulated by the Amyloid Precursor Protein.
- Author
-
Priller, Christina, Bauer, Thomas, Mitteregger, Gerda, Krebs, Bjarne, Kretzschmar, Hans A., and Herms, Jochen
- Subjects
SYNAPSES ,AMYLOID beta-protein precursor ,ALZHEIMER'S disease ,NEURONS ,NERVE endings - Abstract
The amyloid precursor protein (APP) is critical in the pathogenesis of Alzheimer's disease. The question of its normal biological function in neurons, in which it is predominantly located at synapses, is still unclear. Using autaptic cultures of hippocampal neurons, we demonstrate that hippocampal neurons lacking APP show significantly enhanced amplitudes of evoked AMPA- and NMDA-receptor-mediated EPSCs. The size of the readily releasable synaptic vesicle pool was also increased in neurons lacking APP, whereas the release probability was not affected. In addition, the analysis of spontaneous miniature synaptic currents revealed an augmented frequency in neurons lacking APP, whereas the amplitude of miniature synaptic currents was not found to be altered. Together, these findings strongly indicate that lack of APP increases the number of functional synapses. This hypothesis is further supported by morphometric immunohistochemical analysis revealing an increase of synaptophysin-positive puncta per cultured APP knock-out neuron. In conclusion, lack of APP affects synapse formation and transmission in cultured hippocampal neurons. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
39. Towards multicenter β-amyloid PET imaging in mouse models: A triple scanner head-to-head comparison.
- Author
-
Gnörich, Johannes, Koehler, Mara, Wind-Mark, Karin, Klaus, Carolin, Zatcepin, Artem, Palumbo, Giovanna, Lalia, Manvir, Monasor, Laura Sebastian, Beyer, Leonie, Eckenweber, Florian, Scheifele, Maximilian, Gildehaus, Franz-Josef, von Ungern-Sternberg, Barbara, Barthel, Henryk, Sabri, Osama, Bartenstein, Peter, Herms, Jochen, Tahirovic, Sabina, Franzmeier, Nicolai, and Ziegler, Sibylle
- Subjects
- *
IMAGE registration , *POSITRON emission tomography , *ALZHEIMER'S disease , *STAINS & staining (Microscopy) , *CLINICAL drug trials - Abstract
• Three distinct small animal PET scanners show high agreement in Aβ-PET quantification, crucial for multicentric AD research. • Variability in scanner sensitivity affects individual-level interpretation despite stable group differences. • Spatial analysis confirms consistency, while PET imaging correlates well with histological staining, validating its reliability. β-amyloid (Aβ) small animal PET facilitates quantification of fibrillar amyloidosis in Alzheimer's disease (AD) mouse models. Thus, the methodology is receiving growing interest as a monitoring tool in preclinical drug trials. In this regard, harmonization of data from different scanners at multiple sites would allow the establishment large collaborative cohorts and may facilitate efficacy comparison of different treatments. Therefore, we objected to determine the level of agreement of Aβ-PET quantification by a head-to-head comparison of three different state-of-the-art small animal PET scanners, which could help pave the way for future multicenter studies. Within a timeframe of 5 ± 2 weeks, transgenic APPPS1 (n = 9) and wild-type (WT) (n = 8) mice (age range: 13–16 months) were examined three times by Aβ-PET ([18F]florbetaben) using a Siemens Inveon DPET, a MedisonanoScan PET/MR, and a MedisonanoScan PET/CT with harmonized reconstruction protocols. Cortex-to-white-matter 30–60 min p.i. standardized uptake value ratios (SUVR CTX/WM) were calculated to compare binding differences, effect sizes (Cohen's d) and z-score values of APPPS1 relative to WT mice. Correlation coefficients (Pearson's r) were calculated for the agreement of individual SUVR between different scanners. Voxel-wise analysis was used to determine the agreement of spatial pathology patterns. For validation of PET imaging against the histological gold standard, individual SUVR values were subject to a correlation analysis with area occupancy of methoxy‑X04 staining. All three small animal PET scanners yielded comparable group differences between APPPS1 and WT mice (∆ PET =20.4 % ± 2.9 %, ∆ PET/MR =18.4 % ± 4.5 %, ∆ PET/CT =18.1 % ± 3.3 %). Voxel-wise analysis confirmed a high degree of congruency of the spatial pattern (Dice coefficient (DC) PETvs.PET/MR =83.0 %, DC PETvs.PET/CT =69.3 %, DC PET/MRvs.PET/CT =81.9 %). Differences in the group level variance of the three scanners resulted in divergent z-scores (z PET =11.5 ± 1.6; z PET/MR =5.3 ± 1.3; z PET/CT =3.4 ± 0.6) and effect sizes (d PET =8.5, d PET/MR =4.5, d PET/CT =4.1). However, correlations at the individual mouse level were still strong between scanners (r PETvs.PET/MR =0.96, r PETvs.PET/CT =0.91, r PET/MRvs.PET/CT =0.87; all p ≤ 0.0001). Methoxy-X04 staining exhibited a significant correlation across all three PET machines combined (r = 0.76, p < 0.0001) but also at individual level (PET: r = 0.81, p = 0.026; PET/MR: r = 0.89, p = 0.0074; PET/CT: r = 0.93, p = 0.0028). Our comparison of standardized small animal Aβ-PET acquired by three different scanners substantiates the possibility of moving towards a multicentric approach in preclinical AD research. The alignment of image acquisition and analysis methods achieved good overall comparability between data sets. Nevertheless, differences in variance of sensitivity and specificity of different scanners may limit data interpretation at the individual mouse level and deserves methodological optimization. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Microbiota-derived short chain fatty acids modulate microglia and promote Ab plaque deposition.
- Author
-
Colombo, Alessio Vittorio, Sadler, Rebecca Katie, Llovera, Gemma, Singh, Vikramjeet, Roth, Stefan, Heindl, Steffanie, Monasor, Laura Sebastian, Verhoeven, Aswin, Peters, Finn, Parhizkar, Samira, Kamp, Frits, Gomez de Aguero, Mercedes, MacPherson, Andrew J., Winkler, Edith, Herms, Jochen, Benakis, Corinne, Dichgans, Martin, Steiner, Harald, Giera, Martin, and Haass, Christian
- Subjects
- *
FATTY acids , *MICROBIAL metabolites , *MICROGLIA , *PHENOTYPIC plasticity , *GUT microbiome , *ALZHEIMER'S disease - Abstract
Previous studies have identified a crucial role of the gut microbiome in modifying Alzheimer's disease (AD) progression. However, the mechanisms of microbiome-brain interaction in AD were so far unknown. Here, we identify microbiota-derived short chain fatty acids (SCFA) as microbial metabolites which promote Ab deposition. Germ-free (GF) AD mice exhibit a substantially reduced Ab plaque load and markedly reduced SCFA plasma concentrations; conversely, SCFA supplementation to GF AD mice increased the Ab plaque load to levels of conventionally colonized (specific pathogen-free [SPF]) animals and SCFA supplementation to SPF mice even further exacerbated plaque load. This was accompanied by the pronounced alterations in microglial transcriptomic profile, including upregulation of ApoE. Despite increased microglial recruitment to Ab plaques upon SCFA supplementation, microglia contained less intracellular Ab. Taken together, our results demonstrate that microbiota-derived SCFA are critical mediators along the gut-brain axis which promote Ab deposition likely via modulation of the microglial phenotype. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
41. Validity and value of metabolic connectivity in mouse models of β-amyloid and tauopathy.
- Author
-
Ruch, François, Gnörich, Johannes, Wind, Karin, Köhler, Mara, Zatcepin, Artem, Wiedemann, Thomas, Gildehaus, Franz-Joseph, Lindner, Simon, Boening, Guido, von Ungern-Sternberg, Barbara, Beyer, Leonie, Herms, Jochen, Bartenstein, Peter, Brendel, Matthias, and Eckenweber, Florian
- Subjects
- *
TAUOPATHIES , *LABORATORY mice , *ALZHEIMER'S disease , *POSITRON emission tomography , *PATHOLOGICAL physiology - Abstract
• Metabolic connectivity is a valid tool for observation of neuronal network changes. • MC shows significant functional connectivity loss in β-amyloid and tau mouse models. • MC reveals higher agreement with behavior compared to conventional µPET analysis. Among functional imaging methods, metabolic connectivity (MC) is increasingly used for investigation of regional network changes to examine the pathophysiology of neurodegenerative diseases such as Alzheimer's disease (AD) or movement disorders. Hitherto, MC was mostly used in clinical studies, but only a few studies demonstrated the usefulness of MC in the rodent brain. The goal of the current work was to analyze and validate metabolic regional network alterations in three different mouse models of neurodegenerative diseases (β-amyloid and tau) by use of 2-deoxy-2-[18F]fluoro- d -glucose positron emission tomography (FDG-PET) imaging. We compared the results of FDG-µPET MC with conventional VOI-based analysis and behavioral assessment in the Morris water maze (MWM). The impact of awake versus anesthesia conditions on MC read-outs was studied and the robustness of MC data deriving from different scanners was tested. MC proved to be an accurate and robust indicator of functional connectivity loss when sample sizes ≥12 were considered. MC readouts were robust across scanners and in awake/ anesthesia conditions. MC loss was observed throughout all brain regions in tauopathy mice, whereas β-amyloid indicated MC loss mainly in spatial learning areas and subcortical networks. This study established a methodological basis for the utilization of MC in different β-amyloid and tau mouse models. MC has the potential to serve as a read-out of pathological changes within neuronal networks in these models. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Consequences of Pharmacological BACE Inhibition on Synaptic Structure and Function.
- Author
-
Zhu, Kaichuan, Peters, Finn, Filser, Severin, and Herms, Jochen
- Subjects
- *
ALZHEIMER'S disease , *NEURODEGENERATION , *PROTEOLYTIC enzymes , *NEUROPLASTICITY , *LABORATORY mice - Abstract
Abstract Alzheimer’s disease is the most prevalent neurodegenerative disorder among elderly persons. Overt accumulation and aggregation of the amyloid-β peptide (Aβ) is thought to be the initial causative factor for Alzheimer’s disease. Aβ is produced by sequential proteolytic cleavage of the amyloid precursor protein. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) is the initial and rate-limiting protease for the generation of Aβ. Therefore, inhibiting BACE1 is considered one of the most promising therapeutic approaches for potential treatment of Alzheimer’s disease. Currently, several drugs blocking this enzyme (BACE inhibitors) are being evaluated in clinical trials. However, high-dosage BACE-inhibitor treatment interferes with structural and functional synaptic plasticity in mice. These adverse side effects may mask the therapeutic benefit of lowering the Aβ concentration. In this review, we focus on the consequences of BACE inhibition–mediated synaptic deficits and the potential clinical implications. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
43. Rôles physiologiques et pathologiques de la protéine précurseur amyloïde à la présynapse
- Author
-
JORDÀ SIQUIER, Tomàs, Institut Interdisciplinaire des Neurosciences de Bordeaux, Centre National de la Recherche Scientifique (CNRS), Université de Bordeaux, Gaël Barthet, STAR, ABES, Barthet, Gaël, Sans, Nathalie, Herms, Jochen, Gutierrez Perez, Antonia, Kovari, Eniko, and Checler, Frédéric
- Subjects
Presinilin ,Mechanisms Présynaptiques ,Hippocampe ,[SCCO.NEUR]Cognitive science/Neuroscience ,[SCCO.NEUR] Cognitive science/Neuroscience ,mental disorders ,Maladie d'Alzheimer ,Synaptotagmin 7 ,Presynaptic mechanisms ,Alzheimer's disease ,App ,Hippocampus - Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disease which affects 47 million people worldwide, being the most prominent type of dementia. The etiology of the disease is unknown but genetic evidence from the familial form of the disease indicates that the amyloid precursor protein (APP) plays a key role in the pathology. Importantly, APP is the substrate in the proteolytic reaction producing Aβ peptides which compose the amyloid plaques, one of the main pathological hallmarks in AD brain. In addition, APP is ubiquitously expressed by neurons where it interacts with multiple presynaptic proteins but the role of these interactions is elusive.The aim of my thesis was to study the physiological and pathological functions of APP related to its location at the presynapse. First, we studied the consequences on presynaptic mechanisms of the genetic deletion of presenilin, the catalytic subunit of γ-secretase, the intramembrane protease which cleaves APP. We observed that in absence of presenilin, APP accumulates in axons. By combining optogenetic to electrophysiology, we assessed synaptic transmission and plasticity in the CA3 region of the hippocampus. The presynaptic facilitation, the increase in synaptic vesicle release during repetitive stimulation, was altered whereas the basal neurotransmission was not. The impairment of presynaptic mechanisms was due to the accumulation of APP Cter, which decreases the abundancy of synaptotagmin-7, a calcium sensor essential for facilitation. Using a similar approach, we investigated the consequences of the genetic deletion of APP itself and observed again an impairment of presynaptic facilitation. Together, these results demonstrate the importance of APP homeostasis in presynaptic plasticity.I then investigated possible alterations of APP, other than the amyloid peptides, in the AD brain. I discovered that APP dramatically accumulates together with presynaptic proteins around dense-core amyloid plaques in human AD brain. In addition, the Nter domain, but not the Cter domain of APP is enriched in the core of amyloid plaques uncovering a potential pathological role of the secreted APP Nter in dense-core plaques. Ultrastructural analysis of APP accumulations reveals abundant multivesicular bodies containing presynaptic vesicle proteins and autophagosomal built-up of APP. Finally, we observed that outside the APP accumulations, presynaptic proteins were downregulated, in the neuropil area of the outer molecular layer of the dentate gyrus. Altogether, the data I collected during my thesis supports a role of presynaptic APP in physiology and in AD pathology and highlights APP accumulations as a pathological site where presynaptic proteins are mis-distributed., La maladie d'Alzheimer (MA) est une maladie neurodégénérative qui touche 47 millions de personnes dans le monde et représente le type de démence le plus répandu. L'étiologie de la maladie est inconnue mais les preuves génétiques de la forme familiale de la maladie indiquent que la protéine précurseur amyloïde (APP) joue un rôle clé dans la pathologie. L'APP est le substrat de la réaction protéolytique produisant des peptides Aβ qui composent les plaques amyloïdes, l'une des principales caractéristiques pathologiques du cerveau atteint de la MA. De plus, l'APP est exprimée de manière ubiquitaire par les neurones où elle interagit avec plusieurs protéines présynaptiques, mais le rôle de ces interactions est inconnu.Le but de ma thèse était d'étudier les fonctions physiologiques et pathologiques de l'APP liées à sa localisation présynaptique. D’abord, nous avons étudié les conséquences sur les mécanismes présynaptiques de la délétion génétique de la préséniline, la sous-unité catalytique de la γ-sécrétase, la protéase intramembranaire qui clive l'APP. Nous avons observé qu'en l'absence de préséniline, l'APP s'accumule dans les axones. En combinant l'optogénétique à l'électrophysiologie, nous avons évalué la transmission synaptique et la plasticité dans la région CA3 de l'hippocampe. La facilitation présynaptique, l'augmentation de la libération de vésicules synaptiques pendant la stimulation répétitive était réduite alors que la neurotransmission basale ne l'était pas. L'altération des mécanismes présynaptiques était due à l'accumulation d'APP Cter qui diminue l'abondance de synaptotagmine-7, une protéine essentielle à la facilitation. En utilisant une approche similaire, nous avons étudié les conséquences de la suppression génétique de l'APP elle-même et observé à nouveau une altération de la facilitation présynaptique. Dans leur ensemble, ces résultats démontrent l'importance de l'homéostasie de l’APP dans la plasticité présynaptique.J'ai ensuite étudié les altérations possibles de l'APP, en plus des peptides amyloïdes, dans le cerveau de la MA. J'ai découvert que l'APP s'accumule abondamment avec des protéines présynaptiques autour des plaques amyloïdes à noyau dense dans le cerveau humain atteint de la MA. De plus, le domaine Nter, mais pas le domaine Cter de l'APP, est enrichi dans le noyau des plaques amyloïdes révélant un rôle pathologique potentiel de l'APP Nter sécrété dans les plaques à noyau dense. L'analyse ultrastructurale des accumulations de l'APP révèle d'abondants corps multivesiculaires contenant des protéines des vésicules présynaptiques et une accumulation d'APP dans les autophagosomes. Enfin, nous avons observé qu'en dehors des accumulations APP, l’abondance des protéines présynaptiques étaient réduite, dans le neuropile de la couche moléculaire externe du gyrus denté. Dans l'ensemble, les données que j'ai collectées au cours de ma thèse soutiennent un rôle présynaptique de l'APP en physiologie et en pathologie dans la MA et mettent en évidence les accumulations d'APP comme un site pathologique où les protéines présynaptiques sont mal distribuées.
- Published
- 2021
44. Pharmacological Inhibition of BACE1 Impairs Synaptic Plasticity and Cognitive Functions.
- Author
-
Filser, Severin, Ovsepian, Saak V., Masana, Mercè, Blazquez‐Llorca, Lidia, Brandt Elvang, Anders, Volbracht, Christiane, Müller, Marianne B., Jung, Christian K.E., and Herms, Jochen
- Subjects
- *
COGNITIVE ability , *NEUROPLASTICITY , *ENZYME-linked immunosorbent assay , *PHARMACEUTICAL research , *NEURONS - Abstract
Background BACE1 (beta site amyloid precursor protein cleaving enzyme 1) is the rate limiting protease in amyloid β production, hence a promising drug target for the treatment of Alzheimer’s disease. Inhibition of BACE1, as the major β-secretase in vivo with multiple substrates, however is likely to have mechanism-based adverse effects. We explored the impact of long-term pharmacological inhibition of BACE1 on dendritic spine dynamics, synaptic functions, and cognitive performance of adult mice. Methods Sandwich enzyme-linked immunosorbent assay was used to assess Aβ40 levels in brain and plasma after oral administration of BACE1 inhibitors SCH1682496 or LY2811376. In vivo two-photon microscopy of the somatosensory cortex was performed to monitor structural dynamics of dendritic spines while synaptic functions and plasticity were measured via electrophysiological recordings of excitatory postsynaptic currents and hippocampal long-term potentiation in brain slices. Finally, behavioral tests were performed to analyze the impact of pharmacological inhibition of BACE1 on cognitive performance. Results Dose-dependent decrease of Aβ40 levels in vivo confirmed suppression of BACE1 activity by both inhibitors. Prolonged treatment caused a reduction in spine formation of layer V pyramidal neurons, which recovered after withdrawal of inhibitors. Congruently, the rate of spontaneous and miniature excitatory postsynaptic currents in pyramidal neurons and hippocampal long-term potentiation were reduced in animals treated with BACE1 inhibitors. These effects were not detected in Bace1 −/− mice treated with SCH1682496, confirming BACE1 as the pharmacological target. Described structural and functional changes were associated with cognitive deficits as revealed in behavioral tests. Conclusions Our findings indicate important functions to BACE1 in structural and functional synaptic plasticity in the mature brain, with implications for cognition. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
45. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [18F]-florbetaben PET.
- Author
-
Brendel, Matthias, Delker, Andreas, Rötzer, Christina, Böning, Guido, Carlsen, Janette, Cyran, Clemens, Mille, Erik, Gildehaus, Franz Josef, Cumming, Paul, Baumann, Karlheinz, Steiner, Harald, Haass, Christian, Herms, Jochen, Bartenstein, Peter, and Rominger, Axel
- Subjects
- *
AMYLOID , *BRAIN imaging , *LABORATORY mice , *POSITRON emission tomography , *ALZHEIMER'S disease , *BRAIN physiology - Abstract
Abstract: We previously investigated the progression of β-amyloid deposition in brain of mice over-expressing amyloid-precursor protein (APP-Swe), a model of Alzheimer's disease (AD), in a longitudinal PET study with the novel β-amyloid tracer [18F]-florbetaben. There were certain discrepancies between PET and autoradiographic findings, which seemed to arise from partial volume effects (PVE). Since this phenomenon can lead to bias, most especially in the quantitation of brain microPET studies of mice, we aimed in the present study to investigate the magnitude of PVE on [18F]-florbetaben quantitation in murine brain, and to establish and validate a useful correction method (PVEC). Phantom studies with solutions of known radioactivity concentration were performed to measure the full-width-at-half-maximum (FWHM) resolution of the Siemens Inveon DPET and to validate a volume-of-interest (VOI)-based PVEC algorithm. Several VOI-brain-masks were applied to perform in vivo PVEC on [18F]-florbetaben data from C57BL/6(N=6) mice, while uncorrected and PVE-corrected data were cross-validated with gamma counting and autoradiography. Next, PVEC was performed on longitudinal PET data set consisting of 43 PET scans in APP-Swe (13–20months) and age-matched wild-type (WT) mice using the previously defined masks. VOI-based cortex-to-cerebellum ratios (SUVR) were compared for uncorrected and PVE-corrected results. Brains from a subset of transgenic mice were ultimately examined by autoradiography ex vivo and histochemistry in vitro as gold standard assessments, and compared to VOI-based PET results. The phantom study indicated a FWHM of 1.72mm. Applying a VOI-brain-mask including extracerebral regions gave robust PVEC, with increased precision of the SUVR results. Cortical SUVR increased with age in APP-Swe mice compared to baseline measurements (16months: +5.5%, p<0.005; 20months: +15.5%, p<0.05) with uncorrected data, and to a substantially greater extent with PVEC (16months: +12.2% p<0.005; 20months: +36.4% p<0.05). WT animals showed no binding changes, irrespective of PVEC. Relative to autoradiographic results, the error [%] for uncorrected cortical SUVR was 18.9% for native PET data, and declined to 4.8% upon PVEC, in high correlation with histochemistry results. We calculate that PVEC increases by 10% statistical power for detecting altered [18F]-florbetaben uptake in aging APP-Swe mice in planned studies of disease modifying treatments on amyloidogenesis. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
46. Fluorescent rhodanine-3-acetic acids visualize neurofibrillary tangles in Alzheimer’s disease brains.
- Author
-
Anumala, Upendra Rao, Gu, Jiamin, Lo Monte, Fabio, Kramer, Thomas, Heyny-von Haußen, Roland, Hölzer, Jana, Goetschy-Meyer, Valerie, Schön, Christian, Mall, Gerhard, Hilger, Ingrid, Czech, Christian, Herms, Jochen, and Schmidt, Boris
- Subjects
- *
ACETIC acid , *NEUROFIBRILLARY tangles , *ALZHEIMER'S disease diagnosis , *FLUORIMETRY , *BRAIN imaging , *THIAZINES , *HISTOPATHOLOGY - Abstract
Abstract: There is a high demand for the development of an imaging agent for neurofibrillary tangles (NFTs) detection in Alzheimer’s diagnosis. In the present study, a series of rhodanine-3-acetic acids was synthesized and evaluated for fluorescence imaging of NFTs in brain tissues of AD patients. Five out of seven probes have shown excellent binding affinity to NFTs over amyloid plaques in the Thiazine red R displacement assay. However, the selectivity in this in vitro assay is not confirmed by the histopathological evaluation, which indicates significant differences in the binding sites in the assays. Probe 6 showed binding affinity (IC50 =19nM) to tau aggregates which is the highest among this series. Probes 2, 3, 4 and 5 display IC50 values of lower than 100nM to tau aggregates to displace Thiazine red R. Evaluation of the cytotoxicity of these five probes with human liver carcinoma cells revealed that these compounds excert negligible cytotoxicity. The in vivo studies with zebrafish embryos confirmed negligible cytotoxicity at 24 and 72h post fertilization. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
47. Bis(arylvinyl)pyrazines,-pyrimidines, and -pyridazinesAs Imaging Agents for Tau Fibrils and β-Amyloid Plaquesin Alzheimer’s Disease Models.
- Author
-
Boländer, Alexander, Kieser, Daniel, Voss, Constantin, Bauer, Silvia, Schön, Christian, Burgold, Steffen, Bittner, Tobias, Hölzer, Jana, Heyny-vonHaußen, Roland, Mall, Gerhard, Goetschy, Valérie, Czech, Christian, Knust, Henner, Berger, Robert, Herms, Jochen, Hilger, Ingrid, and Schmidt, Boris
- Subjects
- *
ALZHEIMER'S disease , *PYRAZINES , *PYRIMIDINES , *AMYLOID , *TAU proteins , *FLUORESCENCE microscopy , *BIOAVAILABILITY , *TRANSGENIC mice - Abstract
The in vivo diagnosis of Alzheimer’s disease (AD)is ofhigh socioeconomic interest and remains a demanding field of research.The biopathological hallmarks of the disease are extracellular plaquesconsisting of aggregated β-amyloid peptides (Aβ) and tauprotein derived intracellular tangles. Here we report the synthesisand evaluation of fluorescent pyrazine, pyrimidine,and pyridazinederivatives in vitro and in vivo aiming at a tau-based diagnosis ofAD. The probes were pre-evaluated on human brain tissue by fluorescencemicroscopy and were found to label all known disease-related alterationsat high contrast and specificity. To quantify the binding affinity,a new thiazine red displacement assay was developed and selected candidateswere toxicologically profiled. The application in transgenic mousemodels demonstrated bioavailability and brain permeability for onecompound. In the course of histological testing, we discovered anAD-related deposition of tau aggregates in the Bowman’s glandsof the olfactory epithelium, which holds potential for an endoscopicdiagnosis of AD in the olfactory system. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
48. Excitatory synaptic transmission is depressed in cultured hippocampal neurons of APP/PS1 mice
- Author
-
Priller, Christina, Mitteregger, Gerda, Paluch, Sandra, Vassallo, Neville, Staufenbiel, Matthias, Kretzschmar, Hans A., Jucker, Mathias, and Herms, Jochen
- Subjects
- *
NEURAL transmission , *NEUROPHYSIOLOGY , *NEURAL circuitry , *NEUROTRANSMITTERS - Abstract
Abstract: One of the strongest anatomical correlates of the degree of clinical impairment in Alzheimer''s disease is a decrease in synaptic density. A detailed understanding of the pathophysiological mechanism operating at a synaptic level remains incomplete, in particular whether the pre- or the post-synaptic compartment is initially involved. Here, we studied synaptic transmission in autaptic hippocampal cultures from a double-transgenic mouse model (APPPS1, APPswe and PS1L166P) and a single-mutant APP transgenic model (APP23, APPswe). APPPS1 neurons revealed significantly reduced amplitudes of evoked AMPA- and NMDA-receptor-mediated excitatory post-synaptic currents, whereas the amplitudes of spontaneous miniature synaptic responses were not altered. The size of the readily releasable synaptic vesicle pool was also decreased, whereas the release probability was not affected. Morphometric immunohistochemical analysis showed a reduction in synaptophysin-positive puncta. In contrast, we did not identify any alterations in synaptic transmission in neurons derived from single APPswe transgenic mice. Taken together, our findings suggest that cultured neurons of APPPS1 double-transgenic mice have a significantly reduced number of functional excitatory synapses. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
49. Mutant Presenilin 1 Alters Synaptic Transmission in Cultured Hippocampal Neurons.
- Author
-
Priller, Christina, Dewachter, Ilse, Vassallo, Neville, Paluch, Sandra, Pace, Claudia, Kretzschmar, Hans A., van Leuven, Fred, and Herms, Jochen
- Subjects
- *
GENETIC mutation , *PRESENILINS , *ALZHEIMER'S disease , *MICE , *NEURONS , *NEURAL transmission , *SYNAPSES - Abstract
Mutations in presenilins are the major cause of familial Alzheimer disease, but the precise pathogenic mechanism by which presenilin (PS) mutations cause synaptic dysfunction leading to memory loss and neurodegeneration remains unclear, Using autaptic hippocampal cultures from transgenic mice expressing human PS1 with the A246E mutation, we demonstrate that mutant PS1 significantly depressed the amplitude of evoked α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and N-methyl-D-aspartate receptor-mediated synaptic currents. Analysis of the spontaneous miniature synaptic activity revealed a lower frequency of miniature currents but normal miniature amplitude. Both alterations could be rescued by the application of a γ-secretase blocker. On the other hand, the application of synthetic soluble Aβ42 in wild-type neurons induced the PS1 mutant phenotype on synaptic strength. Together, these findings strongly suggest that the expression of mutant PS1 in cultured neurons depresses synaptic transmission by causing a physical reduction in the number of synapses. This hypothesis is consistent with morphometic and semi-quantitative immunohistochemical analysis, revealing a decrease in synaptophysin-positive puncta in PS1 mutant hippocampal neurons. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.